R. Othmen , Z. Oumayma , S. Neji , O. Ferchichi , H. Touati , M.A. Tekaya , S. Kasbaoui , M. Saadi , N. Mejri , A. Ben Halima , E. Bennour , I. Kammoun
{"title":"Cancer therapy-related cardiac dysfunction trajectory in Breast Cancer Patients","authors":"R. Othmen , Z. Oumayma , S. Neji , O. Ferchichi , H. Touati , M.A. Tekaya , S. Kasbaoui , M. Saadi , N. Mejri , A. Ben Halima , E. Bennour , I. Kammoun","doi":"10.1016/j.acvd.2025.04.029","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Cancer therapy-related cardiac dysfunction (CTRCD) is a significant adverse effect of cancer treatments, particularly in breast cancer patients receiving chemotherapy and/or radiation.</div></div><div><h3>Objectives</h3><div>This study describes the trajectory of CTRCD in this population.</div></div><div><h3>Methods</h3><div>A retrospective study was conducted on 77 breast cancer patients who completed chemotherapy. Demographic, clinical, and echocardiographic data were extracted from medical records. The severity of cardiotoxicity was classified as mild, moderate, or severe. Treatment patterns and recovery rates were assessed.</div></div><div><h3>Results</h3><div>Among the 77 patients (mean age 49.1 years), 94.9% received chemotherapy, with 57.7% receiving both anti-HER2 and anthracyclines, 29.5% anthracyclines alone, and 7.7% anti-HER2 alone. Hypertension (19.2%) was the most prevalent cardiovascular risk factor, followed by diabetes (14.1%). Risk stratification (HFA-ICOS) classified 79.5% as low risk, 11.5% as moderate, and 5.1% as high/very high risk. CTRCD occurred in 42.3% of patients, predominantly during chemotherapy (87.9%), with a mean onset of 9.6 months post-treatment. Cardiotoxicity was mild in 75.8%, moderate in 9.1%, and severe in 9.1% of cases, with symptoms in 21.2%. Baseline LVEF declined from 65.7% to 53.1%, and GLS from −21.48 to −16.31 post-toxicity. Regarding management, 60.6% of affected patients received treatment, leading to complete recovery in 51.5% and partial recovery in 9.1%, with a mean recovery time of 6.2 months.</div></div><div><h3>Conclusion</h3><div>CTRCD is common in breast cancer patients, mostly occurring during chemotherapy. Despite declines in LVEF and GLS, treatment led to significant recovery. These findings emphasize the importance of early detection, regular monitoring, and timely intervention to mitigate cardiotoxicity risks.</div></div>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":"118 6","pages":"Page S233"},"PeriodicalIF":2.2000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Cardiovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1875213625002578","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Cancer therapy-related cardiac dysfunction (CTRCD) is a significant adverse effect of cancer treatments, particularly in breast cancer patients receiving chemotherapy and/or radiation.
Objectives
This study describes the trajectory of CTRCD in this population.
Methods
A retrospective study was conducted on 77 breast cancer patients who completed chemotherapy. Demographic, clinical, and echocardiographic data were extracted from medical records. The severity of cardiotoxicity was classified as mild, moderate, or severe. Treatment patterns and recovery rates were assessed.
Results
Among the 77 patients (mean age 49.1 years), 94.9% received chemotherapy, with 57.7% receiving both anti-HER2 and anthracyclines, 29.5% anthracyclines alone, and 7.7% anti-HER2 alone. Hypertension (19.2%) was the most prevalent cardiovascular risk factor, followed by diabetes (14.1%). Risk stratification (HFA-ICOS) classified 79.5% as low risk, 11.5% as moderate, and 5.1% as high/very high risk. CTRCD occurred in 42.3% of patients, predominantly during chemotherapy (87.9%), with a mean onset of 9.6 months post-treatment. Cardiotoxicity was mild in 75.8%, moderate in 9.1%, and severe in 9.1% of cases, with symptoms in 21.2%. Baseline LVEF declined from 65.7% to 53.1%, and GLS from −21.48 to −16.31 post-toxicity. Regarding management, 60.6% of affected patients received treatment, leading to complete recovery in 51.5% and partial recovery in 9.1%, with a mean recovery time of 6.2 months.
Conclusion
CTRCD is common in breast cancer patients, mostly occurring during chemotherapy. Despite declines in LVEF and GLS, treatment led to significant recovery. These findings emphasize the importance of early detection, regular monitoring, and timely intervention to mitigate cardiotoxicity risks.
期刊介绍:
The Journal publishes original peer-reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches, review articles and editorials. Topics covered include coronary artery and valve diseases, interventional and pediatric cardiology, cardiovascular surgery, cardiomyopathy and heart failure, arrhythmias and stimulation, cardiovascular imaging, vascular medicine and hypertension, epidemiology and risk factors, and large multicenter studies. Archives of Cardiovascular Diseases also publishes abstracts of papers presented at the annual sessions of the Journées Européennes de la Société Française de Cardiologie and the guidelines edited by the French Society of Cardiology.